The complexities of breast cancer desmoplasia by Walker, Rosemary A
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
IGF = insulin-like growth factor; PDGF = platelet-derived growth factor; TGF = transforming growth factor; TIMP = tissue inhibitor of metallo-
proteinases.
Available online http://breast-cancer-research.com/content/3/3/143
Introduction
One of the features of many carcinomas, particularly
breast, is the presence of a dense collagenous stroma, the
so-called desmoplastic response, which can be responsi-
ble for the clinical presentation of a tumour as a ‘lump’.
Although studies in the 1950s proposed that the desmo-
plasia represented the condensation of pre-existing colla-
gen [1] there is now good evidence that the collagen is
synthesised by myofibroblasts present in the interstitium
[2,3]. Several mechanisms that result in myofibroblast acti-
vation and collagen synthesis have been proposed. These
include immune cytokine mechanisms and microvascular
injury [4], with features analogous to wound healing [5],
and paracrine activation of myofibroblasts by growth
factors released by tumour cells [6,7]. Various growth
factors, such as transforming growth factor (TGF)-a,
TGF-b, insulin-like growth factor (IGF)-I, IGF-II and
platelet-derived growth factor (PDGF), have been identi-
fied that are secreted by cancer cells and can stimulate
stromal cells [8–11]. It is evident that complex epithelial–
stromal cell interactions exist. Many of the data supporting
this come from studies in vitro, which by their nature are
generally short term.
Histological examination of a range of primary breast carci-
nomas shows that the stromal response can vary from
being predominantly cellular (fibroblasts/myofibroblasts)
with little collagenous tissue, through to a dense collagen
stroma with apparently few stromal cells. The obvious
question is why there are these differences and how the
findings in primary breast carcinomas relate to cell-based
co-culture systems in vitro. There is also a need to under-
stand the nature of the role of the stromal desmoplasia in
cancer progression: does it vary with the transition from
disease in situ to invasive disease?
Xenograft model
To determine the mechanisms of development of desmo-
plasia a more appropriate model system is required. Pre-
vious studies of human tumour xenografts in ‘nude’ mice
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have shown a lack of desmoplastic response [12]. In a
recent paper Shao et al [13] have described a model
system aimed at reproducing the desmoplastic response
in a xenograft system. Their hypothesis was that the
established breast cancer lines used in such models had
a rapid growth rate that might overwhelm any host
stromal response, and that the cells had lost the expres-
sion of critical paracrine growth factors. To test this, they
used a variety of oestrogen-receptor-positive and oestro-
gen-receptor-negative breast cancer cell lines plus three
MCF-7 lines transfected with c-rasH (W9 and W7) or the
neo selectable marker. The rasH transfection had previ-
ously been shown to reduce the growth dependence of
cells for exogenous oestrogen, owing to increased secre-
tion of different growth factors by the transfected cells
[14]. The c-ras MCF-7 was also transfected with a
PDGF-A dominant-negative mutant. Myofibroblasts cul-
tured from desmoplastic breast carcinomas were treated
with conditioned medium from all cell lines, and all lines
were grown as xenografts in oophorectamised nude
mice. All of the breast cancer xenografts grew as cellular
tumours with little or no stroma formation apart from the
tumour formed by W9 grown in the absence of oestro-
gen, which showed a marked desmoplastic response.
Stromal cells comprised 30% of it, there was a high colla-
gen content, and in situ hybridisation demonstrated
stromelysin 3, tissue inhibitor of metalloproteinases
(TIMP)-1 and IGF-II, with a zonal pattern of stromelysin 3
and TIMP-1, as described in primary breast carcinomas
[15,16]. The authors suggest that the induced tumour
parallels a grade I or II breast carcinoma, whereas the
non-desmoplastic xenografts represent cancers of high
histological grade. This extrapolation seems too simple
because several of the cells used were oestrogen recep-
tor positive, the presence of which in primary breast car-
cinomas relates to a better grade and stromal elastosis
[17]. In this respect the model is limited in its reflection of
human breast carcinomas. All of the cell lines examined
expressed significant myofibroblast mitogenic activity,
apart from MDA-MB-157. Analysis of conditioned
medium from W9 cells revealed PDGF to be a major
component of activity. In view of this, W9 was transfected
with a PDGF-A dominant-negative mutant to determine
whether PDGF was the factor causing the desmoplasia.
Secretion of TGF-a, TGF-b1, IGF-I and IGF-II was unaf-
fected, but W9 cells with low PDGF, although tumori-
genic, were non-desmoplastic in the absence of
oestrogen. The conclusions drawn are that PDGF,
secreted by the tumour cells and not host cells, and not
other growth factors, is the primary initiator of the desmo-
plastic response, and that the mechanisms involved are
paracrine rather than immune.
Primary breast carcinomas
This might be so in the model presented, which uses
established human breast cancer cells injected into nude
mice, but is it as simple as this in primary human breast
carcinomas? Shao et al [13] acknowledge that other
paracrine growth factors and inflammatory cell factors
might contribute to tumour desmoplasia but propose that
only PDGF is the major initiator. Examination of PDGF
expression in (pre-invasive) ductal carcinoma in situ of dif-
ferent grades and in invasive carcinomas with differing
stromal responses and behaviours would provide informa-
tion about the role of PDGF. One study of PDGF-AA and
PDGF-BB and their receptors in invasive carcinomas
found expression of PDGF-AA and PDGF-BB in the
cancer cells of 42% and 53% of cases, respectively, but
only PDGFa receptor. Both growth factors and receptors
were present in stromal cells of almost all cases and were
co-expressed in proximity [18]. Although PDGF expres-
sion might have accounted for baseline stromal prolifera-
tion it did not readily explain differences in stromal
proliferation between tumours. However, TGF-b1 and
TGF-b2 and the TGF-b-receptor combination did show
variable expression, which could indicate paracrine
stromal stimulation, in one-third of cases. This could
explain differences in stromal induction between tumours.
There is other evidence for a role for TGF-b1 in stromal
deposition: a significant correlation has been found
between the presence of TGF-b1 in cancer cells and
stromal fibronectin and tenascin [19].
The role of the desmoplastic reaction in breast cancer pro-
gression is still unclear, and it could vary depending on the
nature of the reaction. At the stage of in situ carcinoma
growth factors secreted by the malignant epithelial cells,
either PDGF [13] or TGF-b1 [20], or both, with or without
other factors, could stimulate myofibroblasts within the
adjacent stroma. These could synthesise a variety of
stromal proteins (such as fibronectin, tenascin and colla-
gens 1 and 3), metalloproteinases [21,22] and growth
factors with angiogenic effects [23], which aid invasion,
aid the subsequent growth of cancer cells and promote
metastasis. An understanding of the nature of the growth
factors involved in the stimulation of myofibroblasts is
important for the development of inhibitors that could be
used in the early stages of the disease. However, what is
not clear is whether the dense collagenous stroma seen in
a proportion of invasive breast carcinomas is promoted by
the same stimuli, and whether it promotes or impedes
breast cancer progression. If it is the latter, then identifica-
tion of the mechanism of its formation, and whether there
can be a transition from the tumour-enhancing cellular
form to the dense impeding form, is important for the
development of relevant therapeutic agents.
The evidence presented here favours paracrine growth
factor mechanisms for the induction of the stromal
response, but the role of chemokines [24] and connective
tissue growth factor [25], for example, should not be
ignored.c
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Conclusion
There is still much to understand about the desmoplastic
response, with the need for a model that parallels the tran-
sition from in situ to invasive carcinoma and a more
detailed evaluation of its significance in a range of primary
breast carcinomas.
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